AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
(Source: AbbVie Inc) - 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1) NORTH CHICAGO, Ill. , June 24,...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
NORTH CHICAGO, Ill., April 8, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH CHICAGO,...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating...
View ArticleAbbVie to Present New Data from Hepatitis C Clinical Development Program at...
(Source: AbbVie Inc) - 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline...
View ArticleEnanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless...
(Source: Enanta Pharmaceuticals Inc) 100 percent of genotype 1b (GT1b) patients who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVRin a post-hoc analysis,regardless of whether...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving VIEKIRAX + EXVIERA with or...
View ArticleAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with...
NORTH CHICAGO, Ill., Feb. 27, 2017 /PRNewswire/ -- AbbVie ABBV, +0.24% a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the...
View ArticleAbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® +...
(Source: AbbVie Inc) - RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment - In preliminary data from RUBY-I, patients receiving...
View ArticleResults from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir,...
Visit StreetInsider.com at...
View ArticleAbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir,...
NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug...
View ArticleGilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for...
(Source: Gilead Sciences Inc) - Through Three Years of Treatment, Genvoya Demonstrates Significantly Higher Rates of Virologic Suppression and Favorable Renal and Bone Laboratory Parameters Compared to...
View ArticleGilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for...
SEATTLE, Feb 14, 2017 (BUSINESS WIRE) -- Gilead Sciences, Inc. GILD, -0.15% today announced 144-week data from two Phase 3 studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya...
View ArticleU.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen...
(Source: Gilead Sciences Inc) – Gilead’s First TAF-based Regimen Demonstrates High Efficacy with Improved Renal and Bone Parameters Compared to TDF-based Regimens – FOSTER CITY, Calif.--(BUSINESS...
View ArticleEuropean Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and...
(Source: Bristol-Myers Squibb Company) The European Commission approval is based upon Phase III clinical trial - Reyataz®(atazanavir) and cobicistat combination demonstrated virologic failure rates as...
View ArticleLupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
MUMBAI, India and BALTIMORE, April 28, 2016 /PRNewswire/ -- The only FDA-approved oral uterotonic for the management of PPH, comes to market with a significant investment in professional medical...
View ArticleBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticlePREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Tablets Facebook Twitter Pinterest PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Bottle Facebook Twitter Pinterest PREZCOBIX(TM) Logo Facebook...
View Article